• Je něco špatně v tomto záznamu ?

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

A. Folta, M. Culen, I. Jeziskova, Z. Herudkova, N. Tom, T. Hlubinkova, V. Janeckova, A. Durinikova, J. Vydra, L. Semerad, D. Dvorakova, H. Remesova, E. Cerovska, P. Cetkovsky, P. Jindra, T. Szotkowski, P. Zak, J. Mayer, Z. Racil,

. 2019 ; 186 (2) : 300-310. [pub] 20190409

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023840

In this multi-centre study, we analysed the prognostic impact of mutations in 19 genes associated with myeloid malignancies in 258 newly diagnosed acute myeloid leukaemia patients (aged 19-70 years) undergoing intensive therapy. We identified five patient groups with different prognostic risks and different benefits from allogeneic hematopoietic stem cell transplantation (alloHSCT) within the intermediate cytogenetic risk group patients (n = 184). The most adverse prognosis was observed in patients with DNMT3A and FLT3-ITD co-mutation, whose survival could be significantly improved with alloHSCT. In contrast, the most favourable prognosis without any further benefit from alloHSCT was identified in patients with mutations in NPM1 or CEBPA, after exclusion of the unfavourable prognostic groups defined by mutations in DNMT3A, RUNX1 or genes from chromatin/spliceosome group. An additional analysis of 113 diagnosis-remission paired samples revealed that persistence of non-DNMT3A mutations (above 2% VAF) represented a further negative prognostic factor. The proposed model offers a possible molecular stratification and treatment guidance for intermediate cytogenetic risk group patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023840
003      
CZ-PrNML
005      
20201214131405.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.15916 $2 doi
035    __
$a (PubMed)30968396
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Folta, Adam $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
245    10
$a Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients / $c A. Folta, M. Culen, I. Jeziskova, Z. Herudkova, N. Tom, T. Hlubinkova, V. Janeckova, A. Durinikova, J. Vydra, L. Semerad, D. Dvorakova, H. Remesova, E. Cerovska, P. Cetkovsky, P. Jindra, T. Szotkowski, P. Zak, J. Mayer, Z. Racil,
520    9_
$a In this multi-centre study, we analysed the prognostic impact of mutations in 19 genes associated with myeloid malignancies in 258 newly diagnosed acute myeloid leukaemia patients (aged 19-70 years) undergoing intensive therapy. We identified five patient groups with different prognostic risks and different benefits from allogeneic hematopoietic stem cell transplantation (alloHSCT) within the intermediate cytogenetic risk group patients (n = 184). The most adverse prognosis was observed in patients with DNMT3A and FLT3-ITD co-mutation, whose survival could be significantly improved with alloHSCT. In contrast, the most favourable prognosis without any further benefit from alloHSCT was identified in patients with mutations in NPM1 or CEBPA, after exclusion of the unfavourable prognostic groups defined by mutations in DNMT3A, RUNX1 or genes from chromatin/spliceosome group. An additional analysis of 113 diagnosis-remission paired samples revealed that persistence of non-DNMT3A mutations (above 2% VAF) represented a further negative prognostic factor. The proposed model offers a possible molecular stratification and treatment guidance for intermediate cytogenetic risk group patients.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alografty $7 D064591
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x diagnóza $x genetika $x terapie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a nádorové proteiny $x genetika $7 D009363
650    _2
$a prognóza $7 D011379
650    _2
$a rizikové faktory $7 D012307
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Culen, Martin $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Jeziskova, Ivana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Herudkova, Zdenka $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Tom, Nikola $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Hlubinkova, Tereza $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Janeckova, Veronika $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Durinikova, Anna $u Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Semerad, Lukas $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Dvorakova, Dana $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Remesova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Cerovska, Ela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Cetkovsky, Petr $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Jindra, Pavel $u Department of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic.
700    1_
$a Szotkowski, Tomas $u Department of Hemato-Oncology, University Hospital Olomouc, Olomouc, Czech Republic.
700    1_
$a Zak, Pavel $u Department of Internal Medicine - Department of Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Mayer, Jiri $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Racil, Zdenek $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Department of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 186, č. 2 (2019), s. 300-310
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30968396 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131402 $b ABA008
999    __
$a ok $b bmc $g 1596159 $s 1114516
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 186 $c 2 $d 300-310 $e 20190409 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace